Phaseline

Companies › Novavax

Novavax: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 4; Infectious disease.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
NVX-CoV2705
Omicron JN.1 subvariant SARS-CoV-2 recombinant spike protein vaccine adjuvanted with Matri
SARS-COV-2Phase 4COVID-19–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07086222NVX-CoV2705Phase 4COVID-19Infectious diseaseOct 2026

From the company's SEC filings

Cash and short-term investments of $622m on 2026-09-30; operating cash outflow about $268m a year; runway about 28 months at that burn, to Jan 2029

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Targets

SARS-COV-2 (1)

Companies with the same targets

BioNTech SE Interna Therapeutics

Companies built like this

Valneva Austria Chengdu CoenBiotech Biofabri Vedanta Biosciences Osivax

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.